CIC bioGUNE
Published February 21, 2018 | Version v1
Journal article Open

MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation

Creators

  • 1. Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU), San Sebastian, Spain
  • 2. Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
  • 3. National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain
  • 4. Division of Hepatology, CIMA of the University of Navarra, Pamplona, Spain
  • 5. Proteored-ISCIII, Proteomics Unit, Navarrabiomed, Navarra Health Department, Public University of Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
  • 6. CIC bioGUNE, Bizkaia Technology Park, Derio, Bizkaia, Spain
  • 7. Liver Center, Yale University School of Medicine, New Haven, CT, USA;
  • 8. Department of Gastroenterology, "Università Politecnica delle Marche", Ancona, Italy
  • 9. Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
  • 10. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

Description

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with autoimmune phenomena targeting intrahepatic bile duct cells (cholangiocytes). Although its etiopathogenesis remains obscure, development of antimitochondrial autoantibodies against pyruvate dehydrogenase complex E2 is a common feature. MicroRNA (miR) dysregulation occurs in liver and immune cells of PBC patients, but its functional relevance is largely unknown. We previously reported that miR-506 is overexpressed in PBC cholangiocytes and directly targets both Cl- / HCO3- anion exchanger 2 and type III inositol 1,4,5-trisphosphate receptor, leading to cholestasis. Here, the regulation of miR-506 gene expression and its role in cholangiocyte pathophysiology and immune activation was studied. Several proinflammatory cytokines overexpressed in PBC livers (such as interleukin-8 [IL8], IL12, IL17, IL18, and tumor necrosis factor alpha) stimulated miR-506 promoter activity in human cholangiocytes, as revealed by luciferase reporter assays. Experimental overexpression of miR-506 in cholangiocytes dysregulated the cell proteomic profile (by mass spectrometry), affecting proteins involved in different biological processes including mitochondrial metabolism. In cholangiocytes, miR-506 (1) induced dedifferentiation with down-regulation of biliary and epithelial markers together with up-regulation of mesenchymal, proinflammatory, and profibrotic markers; (2) impaired cell proliferation and adhesion; (3) increased oxidative and endoplasmic reticulum stress; (4) caused DNA damage; and (5) sensitized to caspase-3-dependent apoptosis induced by cytotoxic bile acids. These events were also associated with impaired energy metabolism in mitochondria (proton leak and less adenosine triphosphate production) and pyruvate dehydrogenase complex E2 overexpression. Coculture of miR-506 overexpressing cholangiocytes with PBC immunocytes induced activation and proliferation of PBC immunocytes. CONCLUSION:Different proinflammatory cytokines enhance the expression of miR-506 in biliary epithelial cells; miR-506 induces PBC-like features in cholangiocytes and promotes immune activation, representing a potential therapeutic target for PBC patients. (Hepatology 2018;67:1420-1440).

Files

Figure 1A-C.tif

Files (239.6 MB)

Name Size Download all
md5:4be4a06682aafcfbab383835a5a9658f
7.2 MB Preview Download
md5:d9df9ef76c43ce6a131d033f00df083a
7.3 MB Preview Download
md5:a8cc4c6a6b26e405a6da646c42d069bd
22.3 MB Preview Download
md5:6e023a5555a28bf20036302fa3ddbc86
7.4 MB Preview Download
md5:ad3194825c1cbabc1463908198bf0855
7.2 MB Preview Download
md5:28fa00f09232b162b87a5da33e7386d7
7.3 MB Preview Download
md5:965807dfd3985a707d027c87f1bf675f
24.0 MB Preview Download
md5:f988b3f738766800070bd42335b46a7d
21.7 MB Preview Download
md5:483987cb9ff762388e33723d665d2a0e
7.2 MB Preview Download
md5:f3ba2733175c76e8284956a918f14c70
7.1 MB Preview Download
md5:8948ca10e8eba923a92065812181bae3
7.4 MB Preview Download
md5:9ab87b12dad16b84db9228da3cf32209
7.2 MB Preview Download
md5:3e8e7667c3004e2f4741c8665bf10dc8
7.3 MB Preview Download
md5:eaf0ee5e86c4e294795f4735efe35343
7.3 MB Preview Download
md5:4fc2ce63139cf92300e051de5156a147
22.1 MB Preview Download
md5:e0516cd2d8f0aac70df75ee1e12e60f2
23.7 MB Preview Download
md5:228f28d2aa3049da61396aee9550663a
21.9 MB Preview Download
md5:f143de40a1a8633f1301b43014d71186
21.8 MB Preview Download
md5:0e188d09a79aa5f245fe996458093aaf
291.5 kB Preview Download
md5:33aa33de7673f4bbfea1999d0ebb5ecd
1.9 MB Preview Download

Additional details

Funding

European Commission
CANCERMETAB – Metabolic requirements for prostate cancer cell fitness 336343